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Introduction: The coronavirus disease-2019 (COVID-19) pandemic has been the most
significant event in 2020, with ∼86.8 million cases and 1.88 million deaths worldwide.
It is a highly infectious disease, wherein the virus (severe acute respiratory syndrome
coronavirus 2) rapidly multiplies and spreads to all parts of the body. Therefore,
COVID-19 is not only respiratory disease but also a multisystem disease. Many people,
including physicians, incorrectly believe that the disease affects only the respiratory
tract. In this study, we aimed to describe COVID-19 manifestations and the underlying
pathophysiology to provide the readers with a better understanding of this disease to
achieve good management and to control the spread of this disease.
Methods: Secondary data were obtained from PubMed, Google Scholar, and
Scopus databases. The keywords used for the search were as follows: COVID-19,
COVID-19 pulmonary manifestations, COVID-19 extra pulmonary manifestations, and
pathophysiology of COVID-19. We collected secondary data from systemic reviews,
metaanalyses, case series, and case reports in the form of public data that was published
on websites of the government, medical corporations, medical peer-reviewed journals,
and medical academies, all of which were indexed in PubMed, Google Scholar, or
Scopus. Our questions were as follows: Is COVID-19 a respiratory disease only? and
What are the extrapulmonary manifestations of COVID-19?
Results: From our data, we found that a patient with COVID-19 may be either
asymptomatic or symptomatic. Symptomatic cases may have either pulmonary or
extrapulmonary manifestations. Pulmonary manifestations occur as mild, moderate, or
severe cases. In mild and moderate cases, extrapulmonary manifestations such as
gastroenteritis, fever, or vomitingmay present alone. Some of these casesmay bemissed
for diagnosis, and the patient may receive symptomatic treatment without a COVID-19
diagnosis, leading to increased spread of the infection. Extrapulmonary manifestations
may occur in severe and critical cases as complications of severe infections (high viral
overload) or the cytokine storm, such as in acute kidney injury (AKI), heart failure (HF),
and venous thromboembolic (VTE) manifestation.
Conclusion: COVID-19 is not a respiratory disease alone; rather, it is a multisystem
disease. Pulmonary and extrapulmonary manifestations should be considered for early
diagnosis and to control the spread of the infection.
Keywords: COVID-19, manifestations, pulmonary, extra pulmonary, infection control
Elrobaa and New Manifestations of Covid-19
1. INTRODUCTION
The novel coronavirus disease-2019 (COVID-19) is currently one
of the most rapidly spreading diseases worldwide. The causative
pathogen, severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), is an animal and a human pathogen. The disease
originated in Wuhan City, China, and then spread to the rest of
the world (1). The chief features of the disease are as follows: (1)
a high viral-multiplying capacity, (2) an extensive spread leading
to a high prevalence, (3) being a newly discovered novel disease,
there are no standardized treatment regimens until recently, and
(4) a high mortality rate in some communities (2).
The disease may present as mild, moderate, or severe in
terms of the severity of presentation. The mild disease may be
characterized by symptoms such as body aches, coughs, or mild
fever, while in its moderate form the disease may present with
mild pneumonia along with other symptoms. The severe form of
the disease presence may be characterized by severe pneumonia
and hypoxia. Critical cases with significant hypoxia and organ
failure may need admission to the intensive care unit (ICU) and
mechanical ventilation support (3–5). Besides the symptomatic
cases, asymptomatic cases have also been reported (5–7).
Due to the rapid spread of the disease worldwide, many
countries were forced to close their borders and impose internal
lockdowns to curb the spread. With an incubation period of 14
days (2), the symptoms can be detected∼4–5 days after exposure
(4). Currently, the mortality rate due to the disease is ∼2–5%
according to the community, but it may reach as high as 7% as
observed in Italy (8–10).
Severe and critical forms can be easily identified based
on the presence of SARS symptoms (2) and confirmed with
chest radiography (5). The mild and moderate forms may have
non-specific symptoms such as fever, gastroenteritis, vomiting,
dysgeusia (loss of taste), and headache with no or mild
respiratory symptoms (11). Knowledge of these extrapulmonary
manifestations can help in detecting the mild and moderate
forms, which can aid in early diagnosis, and rapid quarantining
can prevent community spread.
In this review, we have discussed COVID-19 as both a
respiratory tract infection and a multisystem disease. We also
discuss the underlying pathophysiology of the disease and its
manifestations, which can serve as a basis for good management,
treatment, and infection control. In addition, the results of
this study will provide an understanding of the COVID-19,
enabling our medical colleagues to improve the quality of health
care management.
2. METHODS
We collected data on COVID-19 from the databases PubMed,
Google Scholar, and Scopus. We used the following keywords
in our search: COVID-19 pulmonary manifestations,
extrapulmonary manifestations of COVID-19, COVID-19
clinical presentations, the pathophysiology of COVID-19,
and management of COVID-19. We collected secondary
data from systemic reviews, meta-analyses, case series, and
case reports from public data published on websites of the
government, medical corporations, medical peer-reviewed
journals, and medical academies, which were all indexed on
PubMed, Google Scholar, or Scopus. We collected data about
the clinical manifestations, pathophysiological effects, and the
management of the COVID-19 disease. Specific questions were
raised to understand the presentations and manifestations of
COVID-19. Does COVID-19 present exclusively as pulmonary
manifestations only? What are the extrapulmonary presentations
of COVID-19? Complete understanding of COVID-19 in
terms of its pathophysiology and manifestations leads to good
planning regarding the control and prevention of the spread of
the disease.
3. RESULTS
We found two main types of COVID-19 manifestations:
pulmonary and extrapulmonary manifestations. Pulmonary
manifestations are most well-known because these cases
are critical, difficult to manage, and have poor outcomes.
Extrapulmonary manifestations of COVID-19 are common in
moderate and mild cases and may also occur together with
pulmonary manifestations or in severe infection cases, with
multiple complications. Many physicians may not be sufficiently
aware of these extrapulmonary manifestations; therefore, such
cases may be missed to be identified and can cause the spread of
COVID-19 to a greater degree in the community. Asymptomatic
cases of COVID-19 have also been reported. To understand
COVID-19 manifestations, we should understand the underlying
mechanisms and pathophysiology of the disease. Risk factors
that can determine COVID-19 progression in the patient should
be considered. The pathophysiology of COVID-19 may help
in understanding how to treat and manage this disease. Our
results explain the pathophysiology of COVID-19, risk factors
that determine the COVID-19 effect and spread, pulmonary
and extrapulmonary manifestations of COVID-19, and the
management of COVID-19. Refer to Figures 1, 2.
3.1. Pathophysiology of COVID-19
Understanding disease pathophysiology is crucial to understand
the clinical presentation. The coronavirus (CoV) is classified
according to its genotypic form into alpha α, beta β, gamma
γ, and omega o (12). α and β CoVs are the human infecting
forms. SARS-CoV1 and SARS-CoV2 are members of β CoVs,
but SARS-CoV2 has a spike of glycoprotein with a high affinity
to the angiotensin-converting enzyme-2 (ACE2) receptors (13,
14). ACE2 receptors are located in the pulmonary alveolar cell
type II, small intestine, colon, gallbladder, testes, brain stem,
esophagus, heart, and blood vessels in the basal layer of the
epidermis (15–17). This highlights the relation between the
disease symptoms and ACE2 receptor distributions in the human
body (7, 18, 19).
When blood pressure decreases in the renal juxta-
glomerular apparatus, it releases renin into the bloodstream.
Renin acts on angiotensin (from the liver) and converts
it to angiotensin-I. Angiotensin-1, in turn, is converted
into angiotensin-2 by the action of the angiotensin-
converting enzyme (ACE1). Angiotensin-2 has a
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FIGURE 1 | Diagram to explain the presentation of extrapulmonary manifestations of COVID-19.
FIGURE 2 | Diagram to explain the COVID-19 presentations in Health care provider centres.
vasoconstrictor effect that increases blood pressure by
increasing renal perfusion and stimulating aldosterone
release (20).
Angiotensin-converting enzyme-2 has a contrary effect of
ACE1, thereby reducing serum levels of angiotensin-2 (21). ACE2
binds to its receptor and catalyzes the hydrolysis of angiotensin
II to angiotensin. This reduces blood pressure, heart rate, and
alveolar surface tension, which is important for treating acute
respiratory distress syndrome (ARDS) (22). ACE2 is the entry
point for SARS CoV-2 into cells through endocytosis. The
virus, along with the enzyme, is then translocated into the cell
endosome (23).
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Coronavirus disease-2019 spreads through physical contact
and inhalation of infected droplets or air. It then invades
the airway epithelium, where the viral load is increased by
replication. Pyroptosis occurs by the leaking of the virus from
the upper respiratory tract vasculature into the bloodstream,
which then travels to other target organs that have ACE2
receptors. This process induces a T-cell-mediated inflammatory
response, which releases interleukins and cytokines (24).
This cytokine storm may lead to the development of
ARDS (25).
The leaked SARS-CoV-2 then travels to other organs
with ACE2 receptors, leading to extrapulmonary features,
such as gastroenteritis (small intestine); insomnia, dysgeusia,
and headache (brainstem, cerebral cortex, and hypothalamus,
respectively), high blood pressure, and tachycardia (heart and
blood vessels, respectively), and some skin infections (basal
epidermis). ACE2 receptors may be present in the retina and
other eye tissues, leading to conjunctivitis when infected (26, 27).
A host of other immune and inflammatory responses are also
triggered by the infection (15, 28–33).
Many factors can determine the severity of COVID-19,
including viral load, genetic factors, presence of comorbidities,
age, sex, use of immune-suppressive agents, and immunity (34).
Some authors believe that genetic factors also play a role in
the severity of COVID-19 because the ACE2 receptor gene has
multiple polymorphisms, which means that there are multiple
variations in the relationship between SARS-CoV-2 and ACE2
receptor according to ethnicity and gene form. This difference in
a relationship can explain the severity of the disease in a specific
race than others (35).
People with comorbidities such as diabetes mellitus,
hypertension, chronic obstructive pulmonary disease (COPD),
chronic lung disease, chronic kidney disease, cancer, and low
immunity may have a greater affinity for severe infections and
serious complications of COVID-19 (7). Many comorbidities
lead to defects in ACE2 expression (36). For example, patients
with essential hypertension may have defects in the ACE1/ACE2
balance, which leads to severe symptoms of COVID-19 in
that patient. Some studies have suggested that patients with
comorbidities have a more severe form of COVID-19, and
studies that included a high proportion of patients with ARDS
as a complication of COVID-19 showed that the patients had
comorbidities before contracting the infection (37).
Some studies have shown that elderly people have a greater
disease severity than young people (38). Most pulmonary
complications, such as ARDS, are more frequent in the elderly
with COVID-19, and multiple organ failures also occur with
a higher frequency in elderly people with COVID-19 (39).
Immunity and comorbidity are predisposing factors that affect
the complications of COVID-19 in the elderly (40). Some
studies have suggested that ACE2 expression is higher in the
lungs of old people than in the lungs of people of other ages
(41). In addition, the mortality rate is higher in the elderly
group (42).
Many studies have suggested that men are affected more by
COVID-19 than women because the ACE2 expression is higher
in men. Furthermore, the testes may also express ACE2, and
ACE2 levels in the plasma are higher in men than in women.
Some lifestyle factors associated with COVID-19 were smoking,
alcohol consumption, and other factors that are more common in
men than in women. Other studies have shown that critical care
admission was higher in men with COVID-19 than in women
with COVID-19. The mortality rate in men with COVID-19 was
also higher than that in women with COVID-19 (43, 44).
Obesity plays a role in COVID-19 severity because ACE2
expression is higher in adipose tissue (45). Obese people have
a higher risk of respiratory failure and are more frequent
candidates for mechanical ventilation (46). Many COVID-19
critical cases have a higher body mass index (47). The mortality
rate with COVID-19 is higher in obese patients because of
respiratory failure and heart failure [HF; (48)]. Obese people may
also have more comorbidities such as hypertension and diabetes
mellitus, factors that affect COVID-19 severity (49). In essential
hypertension, there is a defect in the ACE/ACE2 balance, and this
is more common in obese patients (50).
3.1.1. Cytokine Storm
The physiological immunological reaction by the innate immune
system can cause an excessive release of proinflammatory
cytokines such as interleukins and cytokines (51). The cause may
be cytomegalovirus and streptococcal A infection or a skin graft.
The excessive release of cytokines and interleukins may lead to a
huge inflammatory process in the body that induces multiorgan
failure and ARDS (52).
Immunity plays a major role in determining the severity
and reactions of COVID-19 (53). Some authors have mentioned
that people with low immunity are at a greater risk for
severe respiratory distress and multiple organ failure due
to COVID-19 (54). In contrast, many studies reported that
a high immune reaction can predispose a cytokine storm
that leads to acute respiratory distress and multiple organ
failure by immune-mediated reactions against the body tissue
and organs. Acute kidney injury (AKI), ARDS, myocarditis,
skin manifestations, ocular manifestations, and neurological
manifestations of COVID-19 may occur due to the cytokine
storm (55). Immunosuppressive agents should not be stopped in
patients who are being treated with these agents. Many studies
have suggested that patients who use cytokine inhibitors do not
exhibit the severe features of COVID-19 because of the inhibitory
action on the hyperinflammatory condition of COVID-19 (56).
Refer to Figure 3.
3.2. Pulmonary Manifestation of COVID-19
Pulmonary manifestations in COVID-19 may be mild, moderate,
and severe (57). Mild cases such as upper respiratory tract
infection (URTI), cough, or sore throat can progress to moderate
and severe degrees (58). The moderate type of pulmonary
presentation of COVID-19 could be pneumonia and fever (59).
The COVID-19 pneumonia type has been reported in some
cases as silent pneumonia with fever or silent pneumonia in a
sick patient (60). We found cases of silent hypoxia as a result
of silent COVID-19 pneumonia (60). The severe manifestation
of COVID-19 is ARDS (61). There are two pathological
mechanisms to explain ARDS in COVID-19 patients. The first
Frontiers in Public Health | www.frontiersin.org 4 September 2021 | Volume 9 | Article 711616
Elrobaa and New Manifestations of Covid-19
FIGURE 3 | Diagram to explain Cytokine storm effect in COVID-19 patient.
mechanism discusses that the ACE2 receptor is located in
pneumocyte type II (62). ACE2 and pneumocyte type 2 play a
role in producing the pulmonary surfactant (62, 63). ACE2 can
improve the blood flow in the alveolar cell, which improves the
alveolar cell function as a pneumocyte type 2, which produces
the pulmonary surfactant (62, 63). The ACE2 receptor is the host
of SARS-COV-2 to the human cell. So when SARS-CoV-2 binds
to ACE2 receptors, it leads to destruction and damage in the
alveolar cells and decreases the pulmonary surfactant that leads to
an increase in the surface tension of the lung and predisposition
to ARDS (62, 63). The second suggested mechanism for ARDS
in COVID-19 patients is the cytokine storm. Cytokine storm is a
hyperimmune response to specific triggers such as viral infections
that lead to a large release of proinflammatory cytokines, such as
cytokines and interleukins, leading to an excessive inflammatory
response that leads to multiple organ failure and destruction in
alveolar cells with ARDS. Multiple factors can determine the
severity of the pulmonary manifestations such as viral overload,
genetic roles and ethnicity, presence of comorbidities, age, and
sex (64). The most common causes of mortality in COVID 19 are
ARDS, severe COVID-19 pneumonia, and multiple organ failure
(65). Refer to Table 1.
3.2.1. Discussion Point
Pulmonary manifestations in COVID-19 may present as URTI
and cough progressing to ARDS or as a sudden stack of
ARD due to silent pneumonia and hypoxia. Sometimes, a
bilateral ground-glass appearance can be seen on a CT scan
for asymptomatic cases of COVID-19. The most common
features of the chest radiographic manifestations of COVID-19
are bilateral infiltration, bilateral ground-glass appearance,
bilateral pneumonia (patches), and pleural effusion. However, the
American College of Radiology recommends not to perform aCT
scan to diagnose COVID-19 in asymptomatic patients (Refer to
below section COVID-19 Manifestations and Diagnosis).
3.3. Cardiovascular Manifestations of
COVID-19
Angiotensin-converting enzyme receptors are located in the
cardiac tissue, and during a SARS-CoV-2 attack, they may
cause cardiac tissue degeneration because the ACE receptors are
affected by SARS-CoV-2. Many cardiac manifestations have been
reported in COVID-19 cases such as arrhythmias, hypertension,
palpitations, myocarditis, myocardial injuries, cardiomyopathies,
and HF (66). Two mechanisms are leading to the response of
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TABLE 1 | Pulmonary manifestations of COVID 19.






Liu, Ping et al. “Epidemiological and clinical
features in patients with coronavirus disease
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Teo, Jason. “Early Detection of Silent Hypoxia in
Covid-19 Pneumonia Using Smartphone Pulse
Oximetry.” Journal of medical systems vol. 44,8
134. 19 Jun.
2020, doi: 10.1007/s10916-020-01587-6
—– ——- *Seen frequently in our
Practice
in HMC, Qatar
Wilkerson, R Gentry et al. “Silent hypoxia: A
harbinger of clinical deterioration in patients with
COVID-19.” The American journal of emergency
medicine vol. 38,10 (2020):
2243.e5-2243.e6. doi: 10.1016/j.ajem.2020.05.044
Case report Case report
ARDS Tzotzos, Susan J et al. “Incidence of ARDS and
outcomes in hospitalized patients with COVID-19:
a global literature survey.” Critical care (London,
England) vol. 24,1 516. 21 Aug. 2020,
doi: 10.1186/s13054-020-03240-7
2212 738 33%
cardiac manifestations of COVID-19. The first is the effect of
SARS–CoV-2 on the ACE2 receptors in the cardiac tissue. The
second mechanism is the cytokine storm that can cause HF
and other cardiac manifestations (67). Viral overload sometimes
determines the severity of the extrapulmonary manifestations,
such as cardiovascular symptoms of COVID-19 (68). Some of
the medications that were used to treat COVID-19-induced
arrhythmias included hydroxychloroquine and chloroquine (69).
Some clinical studies have shown elevated levels of cardiac
enzymes such as troponin T in ICU COVID-19 patients (70).
Elevation in pro BNP levels was also reported in ICU patients.
Some retrospective studies showed diffuse ST elevations in
COVID-19 patients, and urgent coronary angioplasty showed
no coronary obstruction (71). However, myocardial infarction
(MI) was reported in the ICU and hospitalized COVID-19
patients (72). Some authors mentioned arrhythmias in COVID-
19 patients admitted to the ICU; most of these arrhythmias
were paroxysmal atrial fibrillation (73). One of the studies
recorded sudden cardiac death in 19 hospitalized patients; the
patients had an HF with a low ejection fraction. Another
study mentioned Takotsubo cardiomyopathy as one of the
COVID-19 cardiovascular complications (74). Hypertension and
palpitations were reported in many COVID-19 patients in their
first visit to the health care provider. Hypoxia was counted as
the cause of the cardiac arrhythmias and type 2 MIs in COVID-
19 patients. MI in COVID-19 patients may be presented as type
I, which results in the rupture of plaque thrombus, leading to
occlusion of the coronary artery, or may be a result of severe
hypoxia that leads to an ischaemic type II MI (75). Refer to
Table 2.
3.3.1. Discussion Point
The cardiovascular manifestation of COVID-19 may present
initial symptoms, such as palpations, new diagnoses of
hypertension, or chest pains, and may also present as late
symptoms or complications in the ICU or hospitalized COVID-
19 patient. The cardiovascular manifestations were reported in
young, middle-aged, and old age patients with COVID-19.
COVID-19 may induce the following: (1) hypoxia by ARDS
that leads to decreased oxygen supply to the heart muscle,
leading to myocardial degradation and increased troponin T
levels that lead to type II MI, (2) vascular injury due to the
effect of SARS-CoV-2 on endothelial cells that lead to platelet
aggregation and vascular plaques or thrombi that on detachment
block the coronary blood vessels and can induce ischaemic MI.
(3) SARS-CoV-2 has direct effect on ACE2 receptors on the
myocardium that can cause myocarditis. (4) The cytokine storm
may lead to cardiomyopathy and HF. Over-disease stress may
lead to Takotsubo cardiomyopathy. Many viral overloads and
genetic factors play a role in determining the cardiovascular
complications and their severity in COVID-19 patients.
3.4. Gastroenterology Manifestations
The COVID-19 patient may present with loose motion, anorexia,
nausea, vomiting, abdominal pain, epigastric pain, liver injury,
and pancreatic injury. Elevated levels of liver enzymes including
ALT, AST, and alkaline phosphatase have been reported (76).
In addition, high levels of lipase and amylase were reported
in some patients with COVID-19 (77). The mechanism of
Gastrointestinal Tract (GIT) manifestations in COVID-19
depends on three factors: viral overload, and the direct effect of
SARS-CoV-2 on the ACE2 receptors on the epithelium of the
esophagus or mucus layer in the stomach and small intestine
(17). ACE2 is also expressed in the liver tissue (78). The
cytokine storm is considered the third factor that determines
GIT symptoms, and it can induce gastroenteritis symptoms, liver
injury, and pancreatic injury (79, 80). One retrospective study
in China showed that 75% of COVID-19 patients had diarrhea
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41 5 12%
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of patients hospitalized for COVID-19 and cardiac disease
in Northern Italy.” European heart journal vol. 41,19 (2020):
1821-1829. doi: 10.1093/eurheartj/ehaa388






Baldi, Enrico et al. “COVID-19 kills at home: the close
relationship between the epidemic and the increase of
out-of-hospital cardiac arrests.” European heart journal








Bottiroli M, De Caria D, Belli O, et al. Takotsubo syndrome
as a complication in a critically ill COVID-19 patient. ESC
Heart Fail. 2020. https://doi.org/10.1002/ehf2.12912.
Case report
Hypertension Wang, Dawei et al. “Clinical Characteristics of 138
Hospitalized Patients With 2019 Novel
Coronavirus-Infected Pneumonia in Wuhan, China.” JAMA
vol. 323,11 (2020): 1061-1069. doi: 10.1001/jama.2020.1585
138 43 31.2%
Type II MI Shi S, Qin M, Shen B, et al. Association of cardiac injury
with mortality in hospitalized patients with COVID-19 in
Wuhan, China. JAMA Cardiol 2020; https://doi.org/10.
1001/jamacardio.2020.0950
416 82 19.7%
(81). Also, same study reported abdominal pain in COVID-19
patient presentation (81). On other hand, liver injury with an
elevation in liver enzyme reported in COVID 19 patients who
admitted in the ICU (82). Some authors have mentioned acute
pancreatitis as a cytokine storm complication (83). Some drugs,
such as antiviral drugs, are considered hepatotoxic and induce
liver injury in COVID-19 patients (84). The comorbidities, for
example, diabetes mellitus and lifestyle factors including alcohol
consumption, have a role in determining the symptoms and
degree of COVID-19 cases (85). Some studies discovered the
SARS-CoV-2 in the feces of COVID-19 patients (86). However,
another study reported the presence of SARS–CoV-2 in the
epithelium of the esophagus and mucus of the stomach in
COVID-19 patients by endoscopy. However, endoscopy is safe in
cases of GIT bleeding in COVID-19 cases (87). Refer to Table 3.
3.4.1. Discussion Point
GIT symptoms in COVID-19 patients are one of the primary and
initial symptoms that are frequently seen in mild to moderate
cases of COVID-19. The causes of GIT symptoms are as follows:
viral overload, SARS-CoV-2 effect on ACE2 expression in GIT,
and the cytokine storm. COVID-19 patients present with late
symptoms or complications. Diarrhea or loosemotion is themost
frequent primary symptom in COVID-19 patients. However, late
complications that occur in severe infection or critical cases
may include GIT symptoms such as liver injury, pancreatic
injury, and GIT bleeding. GIT endoscope is safe for use in GIT
bleeding management. Epigastric pain and abdominal pain were
considered as primary manifestations of COVID-19 and also
as COVID-19-related GIT manifestations due to gastritis and
abdominal colic.
3.5. Renal Manifestations
The most important renal manifestation of COVID-19 is
AKI. Some studies have shown an increased risk of mortality
in COVID-19 patients who have AKI to a greater extent
than the other patients who have normal kidney function
(88, 89). Haematuria and proteinuria were reported as renal
complications of COVID-19 (90). Some authors have suggested
the direct effect of SARS-CoV-2 on the kidney because ACE2
is expressed in the kidney tissue (91). The ACE2 receptor is
found in renal tubules and may be affected by SARS-CoV-2
(92). The cytokine storm affects kidney function and may induce
acute renal failure (89). Increased blood levels of creatinine and
blood urea nitrogen (BUN) are considered to increase the risk
of hospital death in COVID 19 patients in the ICU (90). A post-
mortem study showed the histopathological feature of acute renal
tubular necrosis in patients who died due to COVID-19 (78).
The viral load may also play a role in the renal manifestations
of COVID-19 (93). Some studies have shown renal function
deterioration in patients with severe pneumonia (94). Patients
with chronic diseases, such as DM and chronic kidney disease,
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TABLE 3 | GIT manifestations.
GIT manifestations References Total patients Affected
patients
Incidence
Loose motion Wan Y et al., 2020. Enteric involvement in hospitalised
patients with COVID-19 outside Wuhan. Lancet
Gastroenterol Hepatol 5: 534–535
230 49 23%
Vomiting, nausea and anorexia
Wu, Yi-Chi et al. “The outbreak of COVID-19: An
overview.” Journal of the Chinese Medical Association :
JCMA vol. 83,3 (2020):
217-220. doi: 10.1097/JCMA.0000000000000270
80 1 1.25 %
Wang, Dawei et al. “Clinical Characteristics of 138
Hospitalized Patients With 2019 Novel
Coronavirus-Infected Pneumonia in Wuhan, China.” JAMA
vol. 323,11 (2020): 1061-1069. doi: 10.1001/jama.2020.1585






Abdominal pain Wang, Dawei et al. “Clinical Characteristics of 138
Hospitalized Patients With 2019 Novel
Coronavirus-Infected Pneumonia in Wuhan, China.” JAMA
vol. 323,11 (2020): 1061-1069. doi: 10.1001/jama.2020.1585
138 3 2.2 %
Epigastric pain Han, Chaoqun et al. “Digestive Symptoms in COVID-19
Patients With Mild Disease Severity: Clinical Presentation,
Stool Viral RNA Testing, and Outcomes.” The American







Pancreatic Injury Liu F, Long X, Zhang B, Zhang W, Chen X, Zhang Z, 2020.
ACE2 expression in pancreas may cause pancreatic










Liver injury Fang D, Jingdong MA, Guan J, Wang M, Song J, Tian D,
Peiyuan LI, 2020. Manifestations of digestive system in
hospitalized patients with novel coronavirus pneumonia in
Wuhan, China: a single-center, descriptive study. Chin J
Dig 40: E005
99 43 43%
GIT bleeding Cavaliere, Kimberly et al. “Management of upper GI
bleeding in patients with COVID-19 pneumonia.”
Gastrointestinal endoscopy vol. 92,2 (2020): 454-455.
doi: 10.1016/j.gie.2020.04.028





TABLE 4 | Acute renal manifestations in COVID 19.





Haematuria Pei, Guangchang et al. “Renal Involvement and
Early Prognosis in Patients with COVID-19
Pneumonia.” Journal of the American Society








Acute kidney injury 35/333 10.5%
Acute tubular necrosis[Arteriosclerosis ] Su, Hua et al. “Renal histopathological analysis
of 26 postmortem findings of patients with








Hyperkalemia Malieckal, Deepa A et al. “Electrolyte
abnormalities in patients hospitalized with
COVID-19.” Clinical kidney journal vol. 14,6
1704-1707. 16 Mar. 2021,
doi: 10.1093/ckj/sfab060
10348 638 6.6%
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Headache Mao, Ling et al. “Neurologic Manifestations of
Hospitalized Patients With Coronavirus Disease 2019 in





Cerebral haemorrhage Craen, Alexandra et al. “Novel Coronavirus Disease
2019 and Subarachnoid Hemorrhage: A Case Report.”
Cureus vol. 12,4 e7846. 27 Apr. 2020,
doi: 10.7759/cureus.7846
Case report Case report
Acute cerebrovascular
disease
Mao, Ling et al. “Neurologic Manifestations of
Hospitalized Patients With Coronavirus Disease 2019 in
Wuhan, China.” JAMA neurology vol. 77,6 (2020):
683-690. doi: 10.1001/jamaneurol.2020.1127
214 6 2.8 %
Ischemic stroke Tan, Y. K., Goh, C., Leow, A., Tambyah, P. A., Ang, A.,
Yap, E. S., Tu, T. M., Sharma, V. K., Yeo, L., Chan, B., &
Tan, B. (2020). COVID-19 and ischemic stroke: a
systematic review and meta-summary of the literature.
Journal of thrombosis and thrombolysis, 50(3), 587–595.
https://doi.org/10.1007/s11239-020-02228-y
362 9 2.5%
Insomnia Kokou-Kpolou, Cyrille Kossigan et al. “Insomnia during
COVID-19 pandemic and lockdown: Prevalence,
severity, and associated risk factors in French
population.” Psychiatry research vol. 290 (2020):
113128. doi: 10.1016/j.psychres.2020.113128
556 18.2%
Huang, Yeen, and Ning Zhao. “Generalized anxiety
disorder, depressive symptoms and sleep quality during
COVID-19 outbreak in China: a web-based
cross-sectional survey.” Psychiatry research vol. 288




Garaci, Francesco et al. “Venous cerebral thrombosis in
COVID-19 patient.” Journal of the neurological sciences
vol. 414 (2020): 116871. doi: 10.1016/j.jns.2020.116871
Case report
Ataxia Mao, Ling et al. “Neurologic Manifestations of
Hospitalized Patients With Coronavirus Disease 2019 in






Gillian bare syndrome Sedaghat Z, Karimi N. Guillain Barre syndrome
associated with COVID-19 infection: A case report. J
Clin Neurosci. 2020 Jun;76:233-235.





Guidon AC, Amato AA. COVID-19 and neuromuscular
disorders. Neurology. 2020; 94(22):959–69
Review
Mao, Ling et al. “Neurologic Manifestations of
Hospitalized Patients With Coronavirus Disease 2019 in
Wuhan, China.” JAMA neurology vol. 77,6 (2020):
683-690. doi: 10.1001/jamaneurol.2020.1127


















AlKetbi, Reem et al. “Acute myelitis as a neurological
complication of Covid-19: A case report and MRI
findings.” Radiology case reports vol. 15,9 1591-1595. 6
Jun. 2020, doi: 10.1016/j.radcr.2020.06.001
Case report
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may have a higher risk of kidney function deterioration with
COVID-19 along with a high mortality rate (95). Hyperkalaemia
may occur in hospitalized patients (96). Refer to Table 4.
3.5.1. Discussion Point
Acute kidney injury is considered one of the COVID-19
manifestations in severe and critical cases. It may also occur as
a complication of COVID-19 pneumonia. Viral overload and
comorbidity may play a role in determining the severity of
AKI in COVID-19. In high viral overload, the ACE2 receptor
has a direct effect from SARS-CoV-2, leading to AKI, and
a cytokine storm that results from high infection may lead
to AKI. Comorbidities, such as diabetic mellitus and chronic
kidney disease, are predisposing factors for AKI in COVID-19
patients or acute on top of chronic kidney disease in COVID-19
patients. Hyperkalaemia is a complication of acute renal failure or
AKI. Proteinuria and haematuria are considered manifestations
of AKI.
3.6. The Neurological Manifestations
The neurological manifestations of COVID-19 may be central
or peripheral symptoms (97). The central nervous symptom
manifestations may be headaches, dizziness, ischaemic stroke,
intracranial hemorrhage, encephalitis, seizures, loss of smell
(dysgeusia), or insomnia (98). Peripheral nervous manifestations
may include neuropraxia, ophthalmoplegia, ataxia, loss of tendon
reflex, Miller Fisher syndrome, and Guillain–Barre syndrome
(99). Acute transverse myelitis with hypotonia has been reported
in some patients with COVID-19 (100). The mechanism of
neurological manifestations of COVID-19 may be because the
SARS-CoV-2 exerts a direct effect on ACE2 receptors that are
distributed in brain tissue (101). Some authors suggested that
SARS-CoV-2 could be ascending by olfactory nerve axons to the
brain and thalamus (101). The autopsy specimen showed brain
edema and degeneration in the nerve ending by a post-mortem
study in the dead body of COVID-19 (98). SARS-CoV 2 has a
hypercoagulopathy effect, which can explain the ischaemic stroke
incident in COVID-19 patients (102). Some studies reported high
fever with a disturbed consciousness level in some of the COVID-
19 patients, and cerebrospinal fluid analysis showed the presence
of SARS-CoV-2. The patients were diagnosed with COVID-
19 and viral encephalitis (103). Seizure disorders have been
previously reported in hospitalized COVID-19 patients without
any history of epilepsy. Retrospective studies of hospitalized
patients reported headache and dizziness in COVID-19 patients
(99, 104). Cerebral hemorrhage occurs in some COVID-19
patients in the ICU (105). Some retrospective studies reported
one patient with cerebral venous thrombosis and another with
cerebral hemorrhage (106). Insomnia was also reported in some
COVID-19 patients even after negative PCR results (107). Early
neurological symptoms of mild COVID-19 patients may involve
loss of smell, headache, and dizziness. Some cases reported
about Guillain–Barre syndrome in a patient with COVID-19 also
reported Miller Fisher syndrome (108, 109). Some retrospective
studies showed peripheral neurological symptoms in COVID-19
patients with ophthalmoplegia and polyneuritis (110). Ataxia has
been reported in COVID-19 patients (111). Acute myelitis with
hypotonia and loss of tendon reflex are also seen (112). Refer to
Table 5.
3.6.1. Discussion Point
The neurological manifestations of COVID-19 may include
primary symptoms such as headache, dizziness, or loss of smell,
or late complications such as cerebral hemorrhage and seizures.
Neurological disorders may occur as complications of vascular
thromboembolic disorder (VTE), causing brain ischaemia and
stroke. The mechanism of nervous system defects in COVID-
19 patients is as follows: (1) The direct effect of SARS-CoV-2 on
ACE2 receptors in the brain and nerve; some authors mention
that SARS-CoV-2 can ascend from the olfactory nerve from the
nasal cavity to the brain thalamus, (2) COVID-19 hypoxia may
have an effect on brain tissue and could lead to brain oedema,
(3) the cytokine storm may have an effect on the central and
peripheral nervous systems, (4) the VTE effect of COVID-19may
lead to brain ischaemia and stroke. Many psychosis cases were
reported in COVID-19 patients. Stroke and cerebral hemorrhage
were reported in COVID-19 patients and acute myelitis with
hypotonia in a patient with COVID-19. Gillian–Barre syndrome
was also reported in COVID-19 patients. The effect of COVID-
19 on the peripheral nervous system may be determined by the
degree of infection as a viral load and the severity of the case that
can cause nervous system complications, as well as the effect of
the virus on the nervous tissue or the complication of hypoxia
and thromboembolic effect that causes nerve ischaemia. Genetic
factors and comorbidities may have a role in the onset of nervous
system manifestations.
3.7. Psychiatric Manifestations
Coronavirus disease-2019 has two categories of psychological
manifestations (113). The first is psychiatric symptoms as a
result of isolation and quarantine, and this type is frequent
and showed depression, anxiety, sleeping disorders, eating
disorders, somatizations, and phobias. The second category is
the psychiatric disorder as a result of the effect of COVID-
19 itself (SARS-CoV-2 in the brain tissue). This type may
be rare but was reported in a case series study for some
patients with COVID-19 who developed psychosis in Spain
(114). One observational study conducted among patients in
isolation reported depression and suicidal ideation in some of
them. Isolated and quarantine people need psychometric support
during the isolation period and after isolation follow-up (115,
116). Refer to Table 6.
3.7.1. Discussion Point
The psychiatric manifestation of COVID-19 may be the
result of the direct effect of SARS-CoV-2 on ACE2 receptors
in the brain, which may manifest as psychosis, lack of
sleep, insomnia, and anxiety. The presentation of psychiatric
manifestations of COVID-19 as a primary symptom may
infrequently be reported and seen in practice. The other type of
psychiatric manifestation of COVID-19 resulted from secondary
causes, such as isolation- and quarantine-related depression.
Depression was reported in people both in quarantine and in
some health care providers who manage COVID-19 patients.
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TABLE 6 | Psycahtric manifestations of COVID 19.









Zhang, Jie et al. “The differential psychological
distress of populations affected by the
COVID-19 pandemic.” Brain, behavior, and
immunity vol. 87 (2020): 49-50.
doi: 10.1016/j.bbi.2020.04.031












sleeping disorders, Huang, Yeen, and Ning Zhao. “Generalized
anxiety disorder, depressive symptoms and
sleep quality during COVID-19 outbreak in
China: a web-based cross-sectional survey.”
Psychiatry research vol. 288 (2020): 112954.
doi: 10.1016/j.psychres.2020.112954
7236 1317 18.2 %
eating disorders, Fernández-Aranda, Fernando et al. “COVID-19
and implications for eating disorders.”
European eating disorders review : the journal
of the Eating Disorders Association vol. 28,3
(2020): 239-245. doi: 10.1002/erv.2738
32 About 12 37.5%
Psychosis after
COVID 19 infection
Rentero, D., Juanes, A., Losada, C. P., Álvarez,
S., Parra, A., Santana, V., Martí, I., & Urricelqui,
J. (2020). New-onset psychosis in COVID-19
pandemic: a case series in Madrid. Psychiatry
research, 290, 113097. https://doi.org/10.1016/
j.psychres.2020.113097
a case series
suicidal ideation Czeisler, Mark É et al. “Mental Health,
Substance Use, and Suicidal Ideation During
the COVID-19 Pandemic - United States, June
24-30, 2020.” MMWR. Morbidity and mortality
weekly report vol. 69,32 1049-1057. 14 Aug.
2020, doi: 10.15585/mmwr.mm6932a1
5,470 About 585 10.7 %
Suicidal ideation was reported in patients in quarantine and
isolation. Therefore, psychiatric support and follow-up may be
required for people in isolation even in health care providers
for COVID-19.
3.8. Skin and Dermatological
Manifestations of COVID-19
Some authors mention the basal layer of the skin as the
location of ACE2 receptors in the human body (117). Two
pathophysiological mechanisms are underlying the cutaneous
manifestations of COVID-19. The first is the direct effect of
SARS-CoV-2 on ACE2 receptors in the basal layer of the skin,
and the second mechanism may be complicated by the effects of
drugs that are used to treat COVID-19, such as skin side effects
due to azithromycin.
The cutaneous manifestations of COVID-19 may appear as
erythema maculopapular redness, skin rash, and erythema. Some
of the quarantine patients experienced skin erythema after a few
days of quarantine. One study showed that COVID-19 patients
presented with skin rash and erythema. Skin manifestations of
COVID-19 may present before respiratory symptoms (118–123).
Refer to Table 7.
3.8.1. Discussion Point
Skin manifestations of COVID-19 are reported as primary
manifestations of COVID-19, also reported as late manifestations
in patients in isolation and quarantine. The pathophysiological
process may be the primary effect of SARS-CoV-2 on ACE2 in the
basal layer of the skin, or secondary to the cytokine storm effect,
or drug reaction used in COVID-19management. Genetic factors
may have a role in the appearance of the dermatological feature
of COVID-19. The dermatological manifestations of COVID-19
are reported in mild and moderate cases of COVID-19.
3.9. Ocular Manifestations
The ocular manifestations of COVID-19 may occur through the
direct effect of SARS–CoV-2, which is transmitted by droplet
infection to the cornea and conjunctiva. The virus present in the
droplets binds with ACE2 receptors located in the conjunctiva
and cornea. SARS-CoV-2 may reach the eyes through systematic
circulation according to the viral load. Some case reports
showed ocular manifestation in COVID-19 as a burning eye
sensation with redness. In addition, foreign body sensation and
conjunctivitis were reported in COVID-19 cases. Some studies
have recommended the use of Goggles to protect the eyes as a
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rash, skin rash and
Erythema
Sachdeva M, Gianotti R, Shah M, Bradanini L,
Tosi D, Veraldi S, Ziv M, Leshem E, Dodiuk-Gad
RP, 2020. Cutaneous manifestations of
COVID-19: report of three cases and a review
of literature. J Dermatol Sci 98: 75–81
3 case report I agree with the result I have
seen COVID 19 with cutaneous
manifestations in my practice in
field hospital FHOIA, HMC,
Qatar.
Joob B, Wiwanitkit V, 2020. COVID-19 can
present with a rash and be mistaken for
dengue. J Am Acad Dermatol 82: e177.
Case report
Recalcati S. Cutaneous manifestations in
COVID-19: a first perspective. J Eur Acad
Dermatol Venereol. 2020;34(5):e212–3.
88 18 20.4%
Tammaro A, Adebanjo GAR, Parisella FR,
Pezzuto A, Rello J. Cutaneous manifestations
in COVID-19: the experiences of Barcelona and
Rome. J Eur Acad Dermatol Venereol.
2020;34(7):e306–7
130 2 1.5%
TABLE 8 | Ocular manifestations of COVID 19.





Zhang X, Chen X, Chen L, Deng C, Zou X, Liu
W, Yu H, Chen B, Sun X, 2020. The evidence of






2 of 72 About 2.78%
Eye redness, conjunctivitis,
foreign body sensation and
burning eye sensation
Chen, Liwen et al. “Ocular manifestations and
clinical characteristics of 535 cases of
COVID-19 in Wuhan, China: a cross-sectional








0.7% of total patient and 14.8 %
of patient with ocular symptoms
Wu P, Duan F, Luo C, Liu Q, Qu X, Liang L, Wu
K, 2020. Characteristics of ocular findings of
patients with coronavirus disease 2019
(COVID-19) in hubei province, China. JAMA
Ophthalmol 138: 575–578.
38 12 31.5%
site of COVID-19 transmission. Some studies have mentioned
conjunctivitis as an early symptom of COVID-19 (26, 27, 124–
128). Refer to Table 8.
3.9.1. Discussion Point
There are two ways for SARS–CoV-2 to reach the eye tissue.
In the first method, droplet infection reaches the eye tissue by
direct contact, and in the second method, it reaches through
blood circulation, which occurs according to the viral overload.
The cytokine storm may have an effect on eye manifestations.
Eye manifestations are reported as primary manifestations of
COVID-19 and may occur as late manifestations.
3.10. Endocrinology Manifestations of
COVID-19
Some observational studies have shown abnormalities in thyroid
function in COVID-19 patients. COVID-19 is a cause of
ketosis in non-diabetes patients and may also create a high
risk for diabetic keto acidosis (DKA) in diabetes patients. One
study reported ketosis in a COVID-19 patient without any
hyperglycaemia, vomiting, or fever. In addition, the pancreatic
injury was reported in 19 cases, and amylase and lipase levels
were elevated. The mechanism of endocrine manifestations may
be because some endocrine glands express ACE2, such as thyroid
and pancreas, or may be due to the hyperimmune feature of the
cytokine storm. Adrenal insufficiency may occur as secondary
adrenal insufficiency in COVID-19 patients as a result of pituitary
hypofunction. Primary adrenal insufficiency is reported as a
result of a thrombotic cause and it is a sign of worsening in
ARDS. The unexplained body aches in COVID-19 patients may
result from a defect in the hypothalamus–pituitary–adrenal axis,
which leads to defective production of ACTH, causing secondary
adrenal insufficiency (131–137) (129–135). Refer to Table 9.
3.10.1. Discussion Point
The endocrine manifestations of COVID-19 may occur as late
manifestations. It has been reported in hospitalized patients.
In addition, it may occur as an initial manifestation, such as
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Manifestations Reference Sample size Affected
patients
Incidence
Ketosis Li, Juyi et al. “COVID-19 infection may cause ketosis
and ketoacidosis.” Diabetes, obesity & metabolism vol.
22,10 (2020): 1935-1941. doi: 10.1111/dom.14057




DKA Li, Juyi et al. “COVID-19 infection may cause ketosis
and ketoacidosis.” Diabetes, obesity & metabolism vol.






0.455 % From total patient
6.4 % out of 658 patients had
ketosis at admission time, they
have no obvious fever or
diarrhoea
Gentile, Sandro et al. “COVID-19, ketoacidosis and
new-onset diabetes: Are there possible cause and
effect relationships among them?.” Diabetes, obesity &





Ghosh, Amerta, and Anoop Misra. “Marked
hyperglycemia and ketosis in a non-obese patient with
new onset diabetes and very mild COVID-19 symptoms:
A case report.” Diabetes & metabolic syndrome vol.
15,1 (2021): 213-214. doi: 10.1016/j.dsx.2020.12.036
Case report I Agree with this case result,
Seen frequently in my practice
in Field hospital FHOIA, HMC,
Qatar
Bode, Bruce et al. “Glycemic Characteristics and
Clinical Outcomes of COVID-19 Patients Hospitalized in
the United States.” Journal of diabetes science and
technology vol. 14,4 (2020): 813-821.
doi: 10.1177/1932296820924469
1122 257 About 22.9% of total patient
Abnormal thyroid
function
Chen, Min et al. “Thyroid Function Analysis in 50
Patients with COVID-19: A Retrospective Study.”
Thyroid : official journal of the American Thyroid
Association, 10.1089/thy.2020.0363. 10 Jul. 2020,
doi: 10.1089/thy.2020.0363
50 32 64%
Adrenal insufficiency Almeida, Madson Q, and Berenice B Mendonca.
“Adrenal Insufficiency and Glucocorticoid Use During
the COVID-19 Pandemic.” Clinics (Sao Paulo, Brazil)
vol. 75 e2022. 12 Jun.
2020, doi: 10.6061/clinics/2020/e2022
review
Heidarpour, M., Vakhshoori, M., Abbasi, S. et al. Adrenal
insufficiency in coronavirus disease 2019: a case
report. J Med Case Reports 14, 134 (2020). https://doi.
org/10.1186/s13256-020-02461-2
Case report
Hashim M, Athar S, Gaba WHNew onset adrenal






Alzahrani, Ali S et al. “The Impact of COVID-19 Viral
Infection on the Hypothalamic-Pituitary-Adrenal Axis.”
Endocrine practice : official journal of the American
College of Endocrinology and the American
Association of Clinical Endocrinologists vol. 27,2 (2021):
83-89. doi: 10.1016/j.eprac.2020.10.014
28 ACTH Level <
10 in [7]
patients
Level < 20 in
[17] patients






Level < 100 in
[8] patients
Level < 200 in
[14] patients





Pancreatic injury Bansal, Priya et al. “Pancreatic Injury in COVID-19
Patients.” The Journal of the Association of Physicians
of India vol. 68,12 (2020): 58-60.
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Okçelik, Sezgin. “COVID-19 pneumonia causes
lower testosterone levels.” Andrologia, e13909.
19 Nov. 2020, doi: 10.1111/and.13909






Decrease Testosterone [T] level
Increase luteinizing hormone LH
T: LH may decrease in COVID 19 patient
Wang, Zhengpin, and Xiaojiang Xu.
“scRNA-seq Profiling of Human Testes Reveals
the Presence of the ACE2 Receptor, A Target
for SARS-CoV-2 Infection in Spermatogonia,
Leydig and Sertoli Cells.” Cells vol. 9,4 920. 9
Apr. 2020, doi: 10.3390/cells9040920




ACE2 represented as :
1.4% in spermatogonia
4.25% in Leydig and
Sertoli cells
Yang, Ming et al. “Pathological Findings in the
Testes of COVID-19 Patients: Clinical
Implications.” European urology focus vol. 6,5
(2020): 1124-1129.
doi: 10.1016/j.euf.2020.05.009
12 11 About 91 % have
testicular injury
DKA in COVID-19 patients with diabetic mellitus. COVID-
19 is one of the causes of ketosis and DKA in diabetes
patients. ACE2 expression is found in many endocrine glands
such as the thalamus, thyroid, pituitary, and pancreas, which
explain the effect of COVID-19 on the endocrine system. The
cytokine storm leads to multiorgan failure and plays a role
in endocrine dysfunction. Blood tests for endocrine function
may require monitoring of endocrine function in hospitalized
COVID-19 patients.
3.11. Testosterone Level (Male
Reproductive System)
Some studies have reported that testosterone (T) levels decreased
in COVID-19 patients, while the luteinizing hormone (LH) levels
increased. Therefore, the T: LH ratio may decrease in COVID-
19 patients (136). The authors mention the testes as one of the
ACE2 receptor sites in the body; however, one study reported
that no RNA of SARS-CoV-2 was found in testicular tissue biopsy
of COVID-19 patients, but the decrease in the T level suggests
Leydig cell damage in the testes (137, 138). However, one study
suggested that high levels of cytokines in COVID-19 patients may
lead to defects in the function of testes and spermatogonia (139).
Refer to Table 10.
3.11.1. Discussion Point
Testosterone decline may be a complication of COVID-19. ACE2
expression is found in testicular tissue and may be affected by
SARS-CoV-2. Cytokine storm has an effect on testicular function.
Testosterone level follow-up is required for hospitalized male
COVID-19 patients.
3.12. Pregnancy
ACE expression is found in the placenta and umbilical cord (140).
Studies showed that neonates were infected with SARS-CoV-
2. There is no confirmed information about the time of viral
infection from the mother to the fetus, whether it occurs in the
first, second, or third trimester (141). Disturbance in maternal–
placental blood flow was reported in pregnant patients with
COVID-19, and placental hypoxia was reported with systemic
hypoxia as a result of COVID-19 in pregnant women (142, 143).
Placental hypoxia and disturbance in placental blood flow may
lead to a decrease in fetal growth, preterm birth, maternal death,
and spontaneous abortion (144). Refer to Table 11.
3.12.1. Discussion Points
COVID-19 has an effect on pregnancy patients in the form
of vertical transmission of the disease from the mother to the
fetus through the umbilical cord. The effect of COVID-19 in
pregnancy depended on the following factors: (1) direct effect
of SARS-CoV-2 on ACE2 receptors on the umbilical cord and
placenta, (2) effect of hypoxia on COVID-19 pneumonia, and (3)
cytokine storm. Pregnant COVID-19 patients need observation
and follow-up about fetal growth, placental blood flow, and
maternal blood oxygen levels.
3.13. Coagulopathy Manifestations
Angiotensin-converting enzyme-2 has receptors on endothelial
cells, indicating that SARS-CoV-2 has a direct effect on
endothelial integrity that can induce VTE disease, which can
cause deep vein thrombosis (DVT) and pulmonary embolism
(PE) (145). The studies showed DVT and PE in hospitalized
COVID-19 patients, especially in old and ICU patients (146).
The D-dimer level increases in COVID-19 patients (147).
Disseminated intermittent coagulopathy (DIC) is reported in
many cases of hospitalized COVID-19 patients (148). Platelets
could be decreased in COVID-19 (149). One study suggested that
ACE2 receptors in platelets indicate the direct effect of SARS-
CoV-2 on platelets, leading to platelet hyperactivity and increased
thrombus formation (150). Refer to Table 12.
3.13.1. Discussion Points
Coagulopathy in COVID-19 leads to thromboembolic
manifestations such as DVT, PE, and brain stroke. The
endothelial cells has ACE2 receptors that may affected by
SARS-COV2. So the blood vessels may lose their integrity, which
leads to platelet aggregation and thrombus formation. DIC is a
complication of COVID-19. The coagulopathy manifestations of
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COVID 19 effect in pregnancy References Sample size Affected
patients
Incidence
Mahyuddin, Aniza P et al. “Mechanisms and
evidence of vertical transmission of infections in
pregnancy including SARS-CoV-2s.” Prenatal
diagnosis vol. 40,13 (2020): 1655-1670.
doi: 10.1002/pd.5765
40 case series
Shanes, Elisheva D et al. “Placental Pathology in
COVID-19.” American journal of clinical pathology
vol. 154,1 (2020): 23-32. doi: 10.1093/ajcp/aqaa089






Disturbance in maternal placenta
blood flow
Placental hypoxia
Wenling, Yao et al. “Pregnancy and COVID-19:
management and challenges.” Revista do Instituto
de Medicina Tropical de Sao Paulo vol. 62 (2020):
e62. doi: 10.1590/s1678-9946202062062
Review
decrease in foetal growth, preterm
birth, maternal death and
spontaneous abortion
Sheth, Sudip et al. “Outcomes in COVID-19 Positive
Neonates and Possibility of Viral Vertical
Transmission: A Narrative Review.” American
journal of perinatology vol. 37,12 (2020): 1208-1216.
doi: 10.1055/s-0040-1714719
Review
Chi J, Gong W, Gao Q. Clinical characteristics and
outcomes of pregnant women with COVID-19 and
the risk of vertical transmission: a systematic
review. Arch Gynecol Obstet. 2020 Dec 1:1–9.
doi: 10.1007/s00404-020-05889-5 Epub ahead of
print. PMID: 33258995; PMCID: PMC7706177.
Systematic
review







7 women were critical ill
24.74% of new-borns
were premature
5 of new-borns had
positive COVID PCR
8 of new born had
negative COVOD PCR
and 3 of them had
elevated IgM and IgG
against SARS –COV2
COVID-19 may be a late manifestation of COVID-19; however,
it could be reported as an initial manifestation or presentation.
3.14. Laboratory Manifestations of
COVID-19
Many studies showed some changes in blood test results as
abnormal values in COVID-19 patients. The studies recorded
decreased lymphocyte and platelet counts and increased lactate
dehydrogenase (LDH), D-dimer, prothrombin time PT, C-
reactive protein (CRP), G6PD, and ferritin (151). Many studies
have suggested the severity of the disease according to the blood
value. For example, COVID-19 patients in the ICU have a low
lymphocyte count (lymphopenia), high LDH, high D-dimer,
and high prothrombin time (152). Another study suggested
that patients need critical care if they have high D-dimer and
CRP levels or thrombocytopenia and lymphopenia (39). The
risk of ARDS is high in COVID-19 patients who have high
D-dimer and low lymphocyte levels (153). The mortality rate
increased with the patients who had high D-dimer levels. CK was
elevated in COVID-19 patients and in that case rhabdomyolysis
was reported in a COVID-19 patient (154). Liver injuries were
reported in some COVID-19 patients with elevated ALT and AST
levels. AKI that occurs in COVID-19 patient is associated with an
elevation in urea, creatinine, and BUN (155). Refer to Figure 4.
3.14.1. Discussion Points
In general, blood testing is a diagnostic and monitoring method.
The laboratory features in ICU and hospitalized COVID-19
patients may have increased CRP, ferritin, creatinine, urea, LDH,
liver enzymes, lipase, D-dimer, and PT. Blood tests may show a
decrease in platelet and lymphocyte counts. Almost all changes in
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Coagulopathy manifestations References Sample size Affected
patients
Incidence
Effect on endothelial integrity that
can induced venous thrombo
embolic disease VTE as DVT and PE
Nägele, Matthias P et al. “Endothelial dysfunction
in COVID-19: Current findings and therapeutic
implications.” Atherosclerosis vol. 314 (2020):
58-62. doi: 10.1016/j.atherosclerosis.2020.10.014
Review
Middeldorp, Saskia et al. “Incidence of venous
thromboembolism in hospitalized patients with
COVID-19.” Journal of thrombosis and













High D dimer Li, Y., Zhao, K., Wei, H., Chen, W., Wang, W., Jia, L.,
Liu, Q., Zhang, J., Shan, T., Peng, Z., Liu, Y., & Yan,
X. (2020). Dynamic relationship between D-dimer
and COVID-19 severity. British journal of
haematology, 190(1), e24–e27. https://doi.org/10.
1111/bjh.16811
279 140 patients 123 patients had much
elevation in D dimer
with poor prognosis
And 23 patients had
improved
Low platelet Zhao, Xiaofang et al. “Early decrease in blood
platelet count is associated with poor prognosis in
COVID-19 patients-indications for predictive,
preventive, and personalized medical approach.”












DIC Seitz, Rainer, and Wolfgang Schramm. “DIC in
COVID-19: Implications for prognosis and
treatment?.” Journal of thrombosis and
haemostasis : JTH vol. 18,7 (2020): 1798-1799.
doi: 10.1111/jth.14878
Letter to editor
laboratory results occur as latemanifestations or complications in
moderate–severe cases of COVID-19.
3.15. Musculoskeletal Manifestations
Generalized bone ache and muscle pain were reported in
COVID-19 patients (156). Rhabdomyolysis was reported in a
COVID-19 patient with high CK and AKI (157). There are two
mechanisms for muscle and bone aches in COVID-19 (161). The
first is the direct effect of SARS–CoV-2 on the ACE 2 receptors in
the muscle and cortex of the bone (158). The second mechanism
is the inflammatory reaction of cytokine storm (164 and 161).
Autoimmune myositis was reported in a COVID-19 patient
(159). Generalized myopathy with muscle loss and weakness was
reported in COVID-19 patients (110). Refer to Table 13.
3.15.1. Discussion Point
Coronavirus disease-140 presented with severe musculoskeletal
pain in some people. The musculoskeletal manifestations may
present as primary or initial symptoms or may present as late
manifestations or complications such as myositis or myopathy.
Rhabdomyolysis was reported in a COVID-19 patient that led
to AKI.
3.16. Initial Manifestations (Symptoms) of
COVID-19
The COVID-19 cases were divided into asymptomatic, mild,
moderate, severe, and critical cases, according to the degree of
infection and severity of the symptoms. Refer to Figures 1, 2.
The initial manifestations of COVID-19 vary. In the mild
cases, the common symptoms were fever, cough, fatigue,
musculoskeletal pain, headache, vomiting, loose motion, sore
throat, cough, palpation, epigastric pain, and abdominal pain.
COVID-19 coughs were reported to be an almost dry cough or
sputum cough. In severe cases, the initial manifestations may
be considered as high-risk symptoms such as respiratory failure,
shock, respiratory distress, arrhythmia, AKI, severe bacterial
infection may be secondary infection, sepsis, septic shock,
and GIT bleeding. Peripheral neuropathy was reported as a
primary manifestation of myopathy. A patient with a moderate
case may present with shortness of breath (SOB) and bilateral
pneumonia (160).
Usually, mild symptoms of COVID-19 are present in healthy
young patients without any comorbidities. Severe symptoms
may be present in patients with comorbidities or old age. Most
at-risk patients who are exposed to COVID-19 may be old,
pregnant, diabetic, and hypertensive, and have hepatic failure or
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FIGURE 4 | Blood values in COVID-19 patients (high severe and critical cases).
TABLE 13 | Musculoskeletal manifestations of COVID 19.
Manifestation References
Bone ache and muscle pain Disser, Nathaniel P et al. “Musculoskeletal Consequences of COVID-19.” The
Journal of bone and joint surgery. American volume vol. 102,14 (2020):
1197-1204. doi: 10.2106/JBJS.20.00847
CDC. Symptoms of Coronavirus. CDC. Available at https://www.cdc.gov/
coronavirus/2019-ncov/symptoms-testing/symptoms.html. May 13, 2020;
Accessed: June 26, 2020.
Rhabdomyolysis and increase in CK level Paliwal, V. K., Garg, R. K., Gupta, A., & Tejan, N. (2020). Neuromuscular
presentations in patients with COVID-19. Neurological sciences : official journal
of the Italian Neurological Society and of the Italian Society of Clinical
Neurophysiology, 41(11), 3039–3056. https://doi.org/10.1007/s10072-020-04708-8
Myositis Beydon, Maxime et al. “Myositis as a manifestation of SARS-CoV-2.” Annals of
the rheumatic diseases, annrheumdis-2020-217573. 23 Apr. 2020,
doi: 10.1136/annrheumdis-2020-217573
Myopathy Guidon, Amanda C, and Anthony A Amato. “COVID-19 and neuromuscular
disorders.” Neurology vol. 94,22 (2020): 959-969.
doi: 10.1212/WNL.0000000000009566
related conditions, ischaemic heart disease, and chronic kidney
disease (160).
Mild symptoms with extra pulmonary manifestations need
health care providers with good clinical sense to diagnose
COVID-19 (160, 161).
Some COVID-19 patients may be asymptomatic and may
continue to be asymptomatic until cure. Some of them present
with severe symptoms. Some of the authors have used the
term “pre-symptomatic phase” for some patients who were first
asymptomatic but then presented with symptoms of COVID-
19. For example, many patients presented to the emergency
department with an SOB, with low oxygen saturation, and
with no history of cough or respiratory symptoms before and
after the chest X-ray showed bilateral pulmonary infiltration in
COVID-19 pneumonia. The incubation period for SARS-CoV-
2 is 14 days, as suggested in some studies, and some studies
report 11.5 days; we refer to the period before the onset of
symptoms as the asymptomatic phase or the pre-symptomatic
phase (161, 162).
The critical case of COVID-19 presented with ARDS or
multiple organ failure. Some of the critical cases started as mild
symptoms then worsened, and some of them were asymptomatic
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and experienced ARDS or multiple organ failure as sudden
attacks (160, 162).
One of the controversies is COVID-19 reinfection. Some
studies have reported immunity toward COVID-19 after
infection recovery. Some of the patients had no immunoglobulin
IgM or IgG after recovery from infection, which may support the
theory of reinfection of COVID-19. However, no case reported
ARDS as a result of reinfection of COVID-19. Viral RNA may
continue after the symptoms resolve during the recovery, but
this does not mean that the patient still has a viral infection
(161–163). Refer to Table 14.
3.17. COVID-19 Manifestations and
Diagnosis
The COVID-19 manifestation can help diagnose COVID-19
patients by Suspicion. For example, the Infectious Disease Society
of America recommends some symptoms for COVID-19 tests
such as critical ill patient, unexplained pneumonia or respiratory
failure, fever, lower respiratory tract symptoms, contact with a
positive case of COVID-19 within 14 days, recent travel during
14 days, immunosuppressed patient with a respiratory infection
or recent admission to the hospital, and health care worker
with fever or respiratory tract infection. However, there are
other symptoms of COVID-19 such as headache, loose motion
and loss of smell, recent insomnia, palpitation, abdominal pain,
epigastric pain, recent arrhythmia, recent brain injury (stroke
or hemorrhage) in any age group, signs of recent peripheral
neuropathy, and AKI, in addition, the unexplained acute liver
or pancreatic injury, recent thyroid function, disturbance, recent
abortion, preterm delivery, or sudden fetal death in pregnant
woman. We have to consider a new onset of hypertension,
especially in young patients, without a family history and new-
onset diabetes mellitus as probably symptoms of COVID19
infection. The principle is when the physician suspects COVID-
19 manifestations as either pulmonary or extrapulmonary,
COVID-19, the investigations are required to rule out COVID-19
infection. May be in the future the COVID-19 PCR or COVID-
19 rapid antigen test will be routine investigations in some
communities to rule out COVID-19 in unexplained symptoms
or disease (31, 164).
Coronavirus disease investigations may involve laboratory
or radiological investigations. Laboratory investigations include
diagnostic studies such as the detection of SARS-CoV-2 RNA,
antigen, or antibodies. Other laboratory tests may include
leukopenia, leucocytosis, lymphopenia, increased LDH levels,
high ferritin levels, unexplained ketosis, and high D-dimer
levels (31).
The CT scan is a diagnostic tool for COVID-19, which
reveals a bilateral ground-glass appearance that discovers silent
pneumonia or the cause of silent hypoxia in many patients
with COVID-19. The common feature of COVID-19 on a
CT scan is the bilateral ground appearance; however, COVID-
19 features may appear on CT as follows: bilateral peripheral
patches, bilateral reticular opacity, bilateral congestion or
vascular thickness, unfrequented pleural effusion (reported), and
lymphadenopathy. However, the American College of Radiology
recommends avoiding the use of CT as a screening tool to
diagnose COVID 19, which should be used only for hospitalized
patients. Other studies have reported the effectiveness of CT
scans in diagnosing asymptomatic COVID-19 patients (165,
166).
An X-ray can be used to diagnose COVID-19 patients, as the
X-ray findings in COVID-19 pneumonia are bilateral infiltration,
patches, or glass-ground appearance (167).
3.18. Radiological Manifestations of
COVID-19
We can explain the appearance of COVID-19 pneumonia in
CT scans, such as multiple patches in the early phase, multiple
ground-glass appearance in the moderate-to-severe case, and
massive pulmonary consolidation in the severe case. As for X-ray
findings, ground-glass appearance is the most common feature,
followed by bilateral infiltration and multiple consolidations.
Pleural effusion is infrequent, but has been reported (167, 168).
Refer to Table 15.
3.19. COVID-19 Manifestations in the
Pediatric Patients
The most common symptoms of COVID-19 in children
are fever, cough, SOB, loose motion, abdominal pain,
muscle ache, nasal flu, vomiting, nasal congestion, skin
rash, conjunctivitis, sore throat, and loss of sense of taste
and smell. X-ray radiography showed bilateral ground-glass
appearance, bilateral patches, and consolidation (169–172). Refer
to Table 16.
3.20. Role of Genes in COVID-19
Manifestations
Some authors believe in the role of the genes in determining the
COVID-19 manifestations and the severity of the manifestations.
The principle is that the ACE2 expression gene G8790A
(rs2285666) has multiple polymorphisms (173). This means
that it has different genotypes, such as A/A genotype, G/G
genotype, and C/T genotype (174). The authors believe that the
gene has different genotypes according to ethnicity. Different
genotypes mean different RNA sequences and may differ in
the susceptibility to SARS-CoV-2, differ in manifestations, and
severity of the manifestations (175). Some Italian authors
believe that the ACE2 genotype C/T is the most common in
Italian people and is more susceptible to SARS-COV-2 than
other genotypes in other ethnicities worldwide. The different
susceptibility to SARS-CoV-2 means that some ethnicities are
more affected by SARS-CoV-2 than others. Higher susceptibility
means more severity and more critical manifestations, while low
susceptibility means less severity with mild manifestations. Some
researchers believe that some genotypes may confer resistance to
SARS-CoV-2, which may explain asymptomatic patients (176).
On other hand, Some of the studies report that people with
blood group A may have more susceptibility to COVID-19 in the
severe form and manifestations, and those with blood group O
may have low susceptibility and more resistance to COVID-19
(177, 178).
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TABLE 14 | COVID 19 manifestations in paediatric.
Manifestations References
Fever, cough, shortness in breath, loose motion,
abdominal pain, muscle ache, nasal flue, vomiting,
nasal congestion, skin Rash, conjunctivitis, sore throat
and loss of sense of taste and smell
- CDC COVID-19 Response Team. Coronavirus disease 2019 in children -
United States, February 12-April 2, 2020. MMWR Morb Mortal Wkly Rep. 2020
Apr 10. 69 (14):422-6. [Medline].
- Lu X, Zhang L, Du H, et al. SARS-CoV-2 infection in children. N Engl J Med. 2020
Apr 23. 382 (17):1663-65.
- Castagnoli R, Votto M, Licari A, et al. Severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic
review. JAMA Pediatr. 2020 Apr 22.
- Foust AM, Phillips GS, Chu WC, et al. International expert consensus statement
on chest imaging in pediatric COVID-19 patient management: imaging findings,
imaging study reporting and imaging study recommendations. Radiology:
Cardiothoracic Imaging. 2020 Apr 23. 2
TABLE 15 | Radiological manifestations for pulmonary COVID 19.
The Radiological Manifestation The References
The X ray feature :
the ground glass appearance is commonest, bilateral
infiltration, multiple consolidations and Pleural effusion
is infrequent but reported
- ACR. ACR Recommendations for the use of Chest Radiography and Computed
Tomography (CT) for Suspected COVID-19 Infection. American College of
Radiology. Available at https://www.acr.org/Advocacy-and-Economics/ACR-
Position-Statements/Recommendations-for-Chest-Radiography-and-CT-for-
Suspected-COVID19-Infection. March 22, 2020; Accessed: April 2, 2020.
CT Feature :
multiple patches in early phase, multiple ground glass
appearance in moderate – sever case and massive
pulmonary consolidation in the sever case
Wang Y, Liu Y, Liu L, Wang X, Luo N, Ling L. Clinical outcome of 55 asymptomatic
cases at the time of hospital admission infected with SARS-Coronavirus-2 in
Shenzhen, China. J Infect Dis. 2020 Mar 17.
Bogoch, I. I., Watts, A., Thomas-Bachli, A., Huber, C., Kraemer, M., & Khan, K.
(2020). Pneumonia of unknown aetiology in Wuhan, China: potential for
international spread via commercial air travel. Journal of travel medicine, 27(2),
taaa008. https://doi.org/10.1093/jtm/taaa008
Li M, Lei P, Zeng B, Li Z, Yu P, Fan B, et al. Coronavirus Disease (COVID-19):
Spectrum of CT Findings and Temporal Progression of the Disease. Acad Radiol.
2020 Mar 20.
TABLE 16 | The initial manifestations [symptoms] of COVID 19.
The Manifestations References
Mild symptoms :
Fever, cough, Fatigue, musculoskeletal pain, Headache,
vomiting, loose motion, sore throat, cough, palpation, epigastric
pain and abdominal pain
- CDC. Symptoms of Coronavirus. CDC. Available at https://www.cdc.gov/
coronavirus/2019-ncov/symptoms-testing/symptoms.html. May 13, 2020;
Accessed: June 26, 2020.
The moderate case may present as SOB and bilateral
pneumonia.
CDC. Coronavirus Disease 2019 (COVID-19): Evaluating and Testing PUI. Centers
for Disease Control and Prevention. Available at https://www.cdc.gov/
coronavirus/2019-ncov/hcp/clinical-criteria.html. May 3, 2020; Accessed: June 9,
2020.
Sever symptoms :
respiratory failure, shock, respiratory distress, arrhythmia,
Acute kidney injury AKI, sever bacterial infection may as
secondary infection, sepsis, septic shock, GIT bleeding
CDC. Interim Clinical Guidance for Management of Patients with Confirmed
Coronavirus Disease (COVID-19). CDC. Available at https://www.cdc.gov/
coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html. June
2, 2020; Accessed: June 9, 2020
Critical case :
as acute respiratory distress syndrome or multiple organs
failure
Gousseff, Marie et al. “Clinical recurrences of COVID-19 symptoms after
recovery: Viral relapse, reinfection or inflammatory rebound?.” The Journal of
infection vol. 81,5 (2020): 816-846. doi: 10.1016/j.jinf.2020.06.073
3.21. COVID-19 Manifestation and
Management
COVID-19 patients were managed according to severity, the
intensity of the manifestations, and type of manifestation, i.e.,
pulmonary and extrapulmonary. The asymptomatic case can be
managed by isolation and quarantine, with a full observation of
any symptoms that may be discovered by the patient. The mild
case of COVID-19 may require quarantine with symptomatic
treatment and close observation (179). The severe and moderate
cases may require hospitalization, images (chest X-ray, CT
scan according to the patient status), blood investigations,
symptomatic treatment, and other types of management, specific
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to COVID-19, such as remdesvir, bamlanivimab, convalescent
plasma, and baricitinib in children (2 years and above).
For pulmonary manifestations, oxygen supplementation and
mechanical ventilation are required according to the severity
of the case. Some research and studies support the use of
dexamethasone as a treatment in COVID-19 lower respiratory
cases (180–182).
Remdesivir has received emergency use approval (EUA) by
the Food and Drug Administration (FDA) on October 20, 2020.
It is an antiviral treatment for adult patients and children from
12 years and above. Convalescent plasma was also approved as
EUA by the FDA in August 2020. Bamlanivimab was approved
for EUA by the FDA on November 9, 2020, and baricitinib
was approved by the FDA as EUA on November 19, 2020
(183–185). Some researchers have suggested the use of renin-
angiotensin system blockers in COVID-19 management. One
hypothesis indicated that ACE2 receptor expressionmay increase
with the use of ACE blockers, which may increase the severity of
infections and manifestations. However, another study showed
no difference in the outcome between the two groups of COVID-
19 patients, wherein one group used an ACE blocker whereas
the other one did not use an ACE blocker. The American Heart
Association does not advise the initiation of ACE blockers and
that its use should be stopped in COVID-19 patients (186, 187).
Chloroquine and hydroxychloroquine are no longer
recommended in the management of COVID-19; the FDA
revoked the EUA on June 15, 2020. Studies showed no significant
effect between the two groups: one used chloroquine, while the
other did not. Choloroquine is an antimalarial drug that can
be used to control the inflammatory response in the body as
SLE and rheumatoid arthritis; however, its use may induce a
dangerous cardiac side effect (179, 188, 189).
Coronavirus disease-2019 patients may have coagulopathy
that leads to microangiopathy, DVT, and PE. Antithrombotic
therapy may be required in critically ill patients who are
on mechanical ventilator support or they may require ICU
admission to decrease mortality. Low-dose anticoagulants may
prevent the deterioration of severe symptoms in hospitalized
patients (190, 191).
Many COVID-19 patients developed new-onset diabetes
mellitus as a result of pancreatic defects from COVID-19.
Insulin should be used to treat diabetes in patients with
COVID-19. Hospitalization is required for obese and chronic
diabetes patients with COVID-19. The hypoglycaemic agent
thiazolidinedione upregulates ACE2 receptors (33, 192, 193).
A British study showed a decrease in the mortality rate in
patients who received low-dose dexamethasone 6mg per day in
comparison with other usual treatment patients. Corticosteroids
may be recommended as a treatment for ARDS and septic shock.
It is not useful in cardiogenic shock. Hydrocortisone 50mg every
8 h per day can be useful in critically-ill COVID-19 patients (194–
196).
Arrhythmia and cardiac manifestations in COVID-19
should be managed according to the guidelines of the
European Resuscitation Council (ERC) and the American
Heart Association (AHA) (67).
Other medications such as immunomodulators, including
interleukin inhibitors and interferons, statins, and nitric oxide
are still under study. Some natural supplements, such as zinc and
vitamin D, are recommended (197–200).
Phosphodiesterase inhibitors, such as ibudilast, may be used as
a macrophage migration inhibitor to manage the cytokine storm.
It has been approved for use in Japan and South Korea for the
treatment of bronchial asthma since 1989. In the USA, ibudilast
has been approved by the FDA after trials (201).
Azithromycin and hydroxychloroquine are no longer
recommended for use in the management of COVID-
19. Studies showed no significant or clinical benefits
in patients with hydroxychloroquine/azithromycin in
comparison with other patients who did not use these
drugs. Hydroxychloroquine/azithromycin may induce QT
prolongation and cardiovascular mortality in COVID-19
patients (202, 203).
Empirical antibiotics are required for severe acute respiratory
symptoms and septic symptoms (196).
4. CONCLUSION
COVID-19 is not only respiratory disease but also a multisystem
disease, and respiratory symptoms may be present or absent
in COVID-19 patients according to multiple factors such as
viral overloading, genetic factors, immune reactions, cytokine
storm, and comorbidities. The other frequent symptoms are
gastrointestinal symptoms and fever. According to the severity of
the case, the patient may also have renal, VTE, cardiac, or central
nervous system manifestations. Skin and ocular manifestations
have also been reported. In addition, peripheral neural disease
was also reported in COVID-19 patients. The pathophysiology
depends on ACE2 expression, cytokine storms, and side effects of
the drugs used. The extra pulmonary manifestations of COVID-
19 should not be neglected and should be fully considered for the
early diagnosis and prevention of the spread of COVID-19.
5. RECOMMENDATIONS
We suggest changing the COVID-19 virus name from severe
acute respiratory syndrome–Corona Virus two (SARS–CoV2)
to severe respiratory and multisystem syndrome–Corona Virus
Two (SRMS-CoV-2) or (SRAMS-CoV-2) because COVID-19 is
not only respiratory disease but also a multisystem disease. We
suggest that, in addition to the name change, extra pulmonary
manifestations should not be ignored by healthcare providers and
should be considered during the diagnosis and management of
COVID 19.
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